Howard McLeod

Howard McLeod has advanced clinical pharmacogenomics in oncology, establishing that germline DPYD mutations predict severe and fatal fluoropyrimidine toxicity and advocating for pretreatment DPYD testing now mandated in Europe. His research demonstrated that pharmacogenomic testing can prevent approximately 30% of severe chemotherapy toxicities through dose individualization based on drug-metabolizing enzyme genotype. He built institutional pharmacogenomics programs integrating preemptive genotyping into routine oncology practice. His work on implementing pharmacogenomics at the point of care has transformed the clinical integration of precision dosing in cancer treatment.